vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and VSE CORP (VSEC). Click either name above to swap in a different company.

VSE CORP is the larger business by last-quarter revenue ($301.2M vs $196.0M, roughly 1.5× Axsome Therapeutics, Inc.). VSE CORP runs the higher net margin — 4.5% vs -14.6%, a 19.1% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 0.7%). VSE CORP produced more free cash flow last quarter ($30.9M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 11.7%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

VSE Corporation is a leading provider of aftermarket distribution and repair services. Operating through its two key segments, VSE significantly enhances the productivity and longevity of its customers' high-value, business-critical assets. The aviation segment is a leading provider of aftermarket parts distribution and maintenance, repair, and overhaul (MRO) services for components and engine accessories to commercial, business, and general aviation operators. The fleet segment specializes i...

AXSM vs VSEC — Head-to-Head

Bigger by revenue
VSEC
VSEC
1.5× larger
VSEC
$301.2M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+64.3% gap
AXSM
65.0%
0.7%
VSEC
Higher net margin
VSEC
VSEC
19.1% more per $
VSEC
4.5%
-14.6%
AXSM
More free cash flow
VSEC
VSEC
$49.6M more FCF
VSEC
$30.9M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
11.7%
VSEC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
VSEC
VSEC
Revenue
$196.0M
$301.2M
Net Profit
$-28.6M
$13.6M
Gross Margin
Operating Margin
-13.8%
10.8%
Net Margin
-14.6%
4.5%
Revenue YoY
65.0%
0.7%
Net Profit YoY
61.9%
3.9%
EPS (diluted)
$-0.55
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
VSEC
VSEC
Q4 25
$196.0M
$301.2M
Q3 25
$171.0M
$282.9M
Q2 25
$150.0M
$272.1M
Q1 25
$121.5M
$256.0M
Q4 24
$118.8M
$299.0M
Q3 24
$104.8M
$273.6M
Q2 24
$87.2M
$266.0M
Q1 24
$75.0M
$241.5M
Net Profit
AXSM
AXSM
VSEC
VSEC
Q4 25
$-28.6M
$13.6M
Q3 25
$-47.2M
$3.9M
Q2 25
$-48.0M
$3.2M
Q1 25
$-59.4M
$-9.0M
Q4 24
$-74.9M
$13.1M
Q3 24
$-64.6M
$11.7M
Q2 24
$-79.3M
$-2.8M
Q1 24
$-68.4M
$-6.6M
Operating Margin
AXSM
AXSM
VSEC
VSEC
Q4 25
-13.8%
10.8%
Q3 25
-27.0%
3.6%
Q2 25
-24.5%
8.3%
Q1 25
-46.9%
9.6%
Q4 24
-61.1%
9.2%
Q3 24
-59.8%
8.7%
Q2 24
-89.5%
2.3%
Q1 24
-89.7%
10.0%
Net Margin
AXSM
AXSM
VSEC
VSEC
Q4 25
-14.6%
4.5%
Q3 25
-27.6%
1.4%
Q2 25
-32.0%
1.2%
Q1 25
-48.9%
-3.5%
Q4 24
-63.1%
4.4%
Q3 24
-61.7%
4.3%
Q2 24
-91.0%
-1.0%
Q1 24
-91.1%
-2.7%
EPS (diluted)
AXSM
AXSM
VSEC
VSEC
Q4 25
$-0.55
$0.64
Q3 25
$-0.94
$0.19
Q2 25
$-0.97
$0.16
Q1 25
$-1.22
$-0.44
Q4 24
$-1.54
$0.79
Q3 24
$-1.34
$0.63
Q2 24
$-1.67
$-0.16
Q1 24
$-1.44
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
VSEC
VSEC
Cash + ST InvestmentsLiquidity on hand
$322.9M
$69.4M
Total DebtLower is stronger
$292.8M
Stockholders' EquityBook value
$88.3M
$1.4B
Total Assets
$689.8M
$2.0B
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
VSEC
VSEC
Q4 25
$322.9M
$69.4M
Q3 25
$325.3M
$8.8M
Q2 25
$303.0M
$16.9M
Q1 25
$300.9M
$5.7M
Q4 24
$315.4M
$29.0M
Q3 24
$327.3M
$7.9M
Q2 24
$315.7M
$19.0M
Q1 24
$331.4M
$10.6M
Total Debt
AXSM
AXSM
VSEC
VSEC
Q4 25
$292.8M
Q3 25
$356.1M
Q2 25
$379.2M
Q1 25
$465.0M
Q4 24
$430.2M
Q3 24
$450.3M
Q2 24
$463.5M
Q1 24
$481.6M
Stockholders' Equity
AXSM
AXSM
VSEC
VSEC
Q4 25
$88.3M
$1.4B
Q3 25
$73.7M
$983.3M
Q2 25
$73.1M
$979.5M
Q1 25
$53.2M
$975.7M
Q4 24
$57.0M
$988.2M
Q3 24
$92.9M
$787.8M
Q2 24
$102.9M
$781.3M
Q1 24
$144.0M
$612.7M
Total Assets
AXSM
AXSM
VSEC
VSEC
Q4 25
$689.8M
$2.0B
Q3 25
$669.3M
$1.6B
Q2 25
$639.8M
$1.6B
Q1 25
$596.7M
$1.7B
Q4 24
$568.5M
$1.7B
Q3 24
$561.5M
$1.5B
Q2 24
$548.2M
$1.5B
Q1 24
$545.7M
$1.3B
Debt / Equity
AXSM
AXSM
VSEC
VSEC
Q4 25
0.20×
Q3 25
0.36×
Q2 25
0.39×
Q1 25
0.48×
Q4 24
0.44×
Q3 24
0.57×
Q2 24
0.59×
Q1 24
0.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
VSEC
VSEC
Operating Cash FlowLast quarter
$-18.7M
$37.6M
Free Cash FlowOCF − Capex
$-18.7M
$30.9M
FCF MarginFCF / Revenue
-9.6%
10.3%
Capex IntensityCapex / Revenue
0.0%
2.2%
Cash ConversionOCF / Net Profit
2.77×
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$5.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
VSEC
VSEC
Q4 25
$-18.7M
$37.6M
Q3 25
$1.0M
$24.1M
Q2 25
$-32.4M
$11.9M
Q1 25
$-43.4M
$-46.6M
Q4 24
$-26.2M
$55.4M
Q3 24
$-18.6M
$10.2M
Q2 24
$-30.1M
$-17.5M
Q1 24
$-53.5M
$-79.1M
Free Cash Flow
AXSM
AXSM
VSEC
VSEC
Q4 25
$-18.7M
$30.9M
Q3 25
$988.0K
$18.0M
Q2 25
$-32.4M
$6.3M
Q1 25
$-43.7M
$-49.5M
Q4 24
$-26.2M
$52.1M
Q3 24
$-18.7M
$4.4M
Q2 24
$-30.2M
$-21.5M
Q1 24
$-53.6M
$-86.8M
FCF Margin
AXSM
AXSM
VSEC
VSEC
Q4 25
-9.6%
10.3%
Q3 25
0.6%
6.4%
Q2 25
-21.6%
2.3%
Q1 25
-36.0%
-19.3%
Q4 24
-22.1%
17.4%
Q3 24
-17.9%
1.6%
Q2 24
-34.6%
-8.1%
Q1 24
-71.4%
-35.9%
Capex Intensity
AXSM
AXSM
VSEC
VSEC
Q4 25
0.0%
2.2%
Q3 25
0.0%
2.1%
Q2 25
0.0%
2.1%
Q1 25
0.3%
1.1%
Q4 24
0.0%
1.1%
Q3 24
0.1%
2.1%
Q2 24
0.1%
1.5%
Q1 24
0.1%
3.2%
Cash Conversion
AXSM
AXSM
VSEC
VSEC
Q4 25
2.77×
Q3 25
6.16×
Q2 25
3.72×
Q1 25
Q4 24
4.24×
Q3 24
0.87×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons